Hospital
Terrebonne Parish Hospital Service District #1
Terrebonne Parish Hospital Service District #1 was paid $16.20M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoTERREBONNE PARISH HOSPITAL SERVICE DISTRICT #1
HOUMA, LA 70360
HOUMA, LA 70360
33aNPI1518924109assigned 04/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.20M
24GClaims490,270
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#27 of 96
Median peer was paid$5.17M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,602 | $1.76M | |
| 2019 | 75,926 | $2.13M | |
| 2020 | 52,784 | $1.47M | |
| 2021 | 63,872 | $2.05M | |
| 2022 | 72,224 | $2.48M | |
| 2023 | 90,649 | $3.08M | |
| 2024incomplete | 66,213 | $3.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 46,054 | 41,873 | $4.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 18,571 | 16,744 | $2.68M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 40,220 | 37,308 | $2.66M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.1% | 8,351 | 7,480 | $834K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 16,218 | 15,166 | $705K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 17,851 | 15,868 | $347K |
| 80053 | Comprehensive metabolic panel | 2.0% | 50,654 | 43,012 | $329K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 16,552 | 13,691 | $316K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 7,680 | 7,343 | $269K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 7,670 | 7,343 | $269K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 12,857 | 11,467 | $250K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 6,030 | 5,480 | $247K |
109 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 1,893 | $233K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 49,419 | $232K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,377 | $219K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 15,644 | $192K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 10,008 | $192K |
| 88142 | 1.1% | 12,693 | $178K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,459 | $141K |
| G0378 | Hospital observation service, per hour | <1% | 2,025 | $139K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,839 | $114K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 358 | $106K |
| 81025 | <1% | 15,907 | $102K | |
| 87400 | <1% | 10,511 | $76K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,486 | $72K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,216 | $72K |
| 84484 | <1% | 10,021 | $63K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 843 | $59K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,364 | $47K |
| 81001 | <1% | 18,544 | $43K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,545 | $37K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,452 | $30K |
| 83690 | <1% | 5,741 | $28K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 255 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 959 | $20K |
| 83655 | <1% | 1,555 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,054 | $18K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,186 | $18K |
| 59025 | Fetal non-stress test | <1% | 275 | $16K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 401 | $14K |
| 80061 | Lipid panel | <1% | 1,785 | $14K |
| 81003 | <1% | 8,357 | $13K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 517 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 849 | $11K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 409 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,604 | $10K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 124 | $9K |
| 83880 | <1% | 393 | $8K | |
| 87807 | <1% | 558 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,420 | $7K |
| 84439 | <1% | 1,361 | $7K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 104 | $6K |
| 0002A | <1% | 146 | $6K | |
| 0004A | <1% | 168 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 996 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 900 | $5K |
| 80306 | <1% | 362 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 165 | $5K |
| 0001A | <1% | 113 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 322 | $4K |
| 84702 | <1% | 371 | $4K | |
| 87081 | <1% | 605 | $4K | |
| 85027 | <1% | 852 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 149 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,089 | $4K |
| 82962 | <1% | 1,208 | $3K | |
| 96376 | <1% | 195 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 85 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 784 | $3K |
| 83735 | <1% | 647 | $2K | |
| 82247 | <1% | 534 | $2K | |
| 82248 | <1% | 539 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 602 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 25 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $1K |
| 87070 | <1% | 160 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 57 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 642 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 103 | $1K |
| 86769 | <1% | 37 | $1K | |
| 0003A | <1% | 24 | $782.62 | |
| 82607 | <1% | 70 | $728.94 | |
| 82746 | <1% | 68 | $695.43 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $673.96 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 75 | $672.26 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 343 | $663.16 |
| 90715 | <1% | 15 | $610.63 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 335 | $590.38 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 251 | $491.19 |
| 85651 | <1% | 118 | $454.85 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 192 | $421.63 |
| 0124A | <1% | 22 | $410.89 | |
| 84480 | <1% | 86 | $373.84 | |
| 73130 | <1% | 12 | $358.92 | |
| 86140 | <1% | 55 | $329.50 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 26 | $328.90 |
| 83605 | <1% | 25 | $188.47 | |
| 96160 | <1% | 12 | $113.38 | |
| 82550 | <1% | 17 | $65.83 | |
| 91300 | <1% | 437 | $62.70 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 120 | $47.13 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $46.93 |
| 85610 | <1% | 18 | $38.74 | |
| 86850 | <1% | 17 | $33.90 | |
| J2704 | Injection, propofol, 10 mg | <1% | 572 | $27.28 |
| 82043 | <1% | 12 | $23.12 | |
| 82570 | <1% | 12 | $20.72 | |
| 86901 | <1% | 17 | $15.04 | |
| 86900 | <1% | 17 | $15.04 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 95 | $13.84 |
| 91312 | <1% | 24 | $0.02 | |
| 91305 | 0% | 15 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 775 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 18 | $0.00 |
| 80320 | 0% | 21 | $0.00 | |
| 99490 | Ccm add 20min | 0% | 108 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYEATES, FRANCES (EXECUTIVE VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Anesthesia Associates of Bayou Region LLC | Houma, LA | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.